A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
GO45434
Phase 2 other active
Quick answer
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) is a Phase 2 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
- Phase
- Phase 2
- Modality
- other
- Status
- active